Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors
Oncotarget2017Vol. 8(34), pp. 57379–57385
Citations Over TimeTop 20% of 2017 papers
Abstract
The use of ALK-TKIs significantly increases the risk of developing high-grade ILD and QTc prolongation in lung cancer patients. Clinicians should pay attention to the risks of severe ILD and QTc prolongation with the administration of these drugs.
Related Papers
- → Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large‐cell lymphoma and inflammatory myofibroblastic tumor(2002)286 cited
- → The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer(2015)3 cited
- → Complex variant translocation t(1;2) with TPM3-ALK fusion due to cryptic ALK gene rearrangement in anaplastic large-cell lymphoma.(1999)49 cited
- → [Diagnosis for ALK positive non-small cell lung cancer].(2015)